Skip to main content

Advertisement

SpringerLink
Log in

Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Discovery of an endocannabinoid signaling system launched the development of the blocker rimonabant, a cannabinoid CB1 receptor (CB1R) antagonist/inverse agonist. Due to untoward effects, this medication was withdrawn and efforts have been directed towards discovering chemicals with more benign profiles.

Objective

This study aims to comparatively evaluate new ligands using a rimonabant discriminated drinking aversion procedure.

Methods

Rats discriminated between rimonabant (5.6 mg/kg) and vehicle. The 30 min saccharin (0.1%) drinking after rimonabant pretreatment was followed by injection of lithium chloride (120 mg/kg) in the experimental animals. After vehicle pretreatment, experimental animals were given i.p. NaCl (10 ml/kg). Postdrinking treatment for controls was NaCl, irrespective of pretreatment condition (rimonabant or vehicle).

Results

The centrally acting neutral CB1R antagonist AM4113, but not the limited brain penetrating CB1R neutral antagonist AM6545, substituted for rimonabant. The CB1R agonists THC (1–10 mg/kg), AM1346 (1–10 mg/kg) did not substitute. The rimonabant-induced conditioned suppression of saccharin drinking was attenuated when CB1R agonists AM5983 (0.01–1 mg/kg) and THC (10 mg/kg), but not the CB1R agonist AM1346 (0.1–18 mg/kg), were combined with rimonabant (5.6 mg/kg). By varying the injection-to-test interval, we gauged the relative duration of the cueing effects of rimonabant, and the in vivo functional half-life was estimated to be approximately 1.5 h.

Conclusion

A neutral CB1R antagonist (AM4113) produced cueing effects similar to those of rimonabant and generalization likely was centrally mediated. The functional cueing effects of rimonabant are relatively short-acting, pharmacologically selective, and differentially blocked by cannabinergics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Baskfield CY, Martin BR, Wiley JL (2004) Differential effects of delta-9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. J Pharmacol Exp Ther 309:86–91

    Article  PubMed  CAS  Google Scholar 

  • Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, Makriyannis A, Sharkey KA (2007) A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185–R2193

    Article  PubMed  CAS  Google Scholar 

  • Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, Lutz B, Zimmer A, Parker LA, Makriyannis A, Sharkey KA (2010) A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 161:629–642

    Article  PubMed  CAS  Google Scholar 

  • Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451–463

    Article  PubMed  CAS  Google Scholar 

  • Colpaert FC, Niemegeers CJ, Janssen PA (1975) Differential response control by isopropamide: a peripherally induced discriminative cue. Eur J Pharmacol 34:381–384

    Article  PubMed  CAS  Google Scholar 

  • Colpaert FC, Kuyps JJ, Niemegeers CJ, Janssen PA (1976) Discriminative stimulus properties of a low dl-amphetamine dose. Arch Int Pharmacodyn Thér 223:34–42

    PubMed  CAS  Google Scholar 

  • Davis CM, Stevenson GW, Canadas F, Ullrich T, Rice KC, Riley AL (2009) Discriminative stimulus properties of naloxone in Long–Evans rats: assessment with the conditioned taste aversion baseline of drug discrimination learning. Psychopharmacol Berl 203:421–429

    Article  CAS  Google Scholar 

  • Di Marzo V (2010) Anandamide serves two masters in the brain. Nat Neurosci 13:1446–1448

    Article  PubMed  Google Scholar 

  • Hanus LO (2009) Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev 29:213–271

    Article  PubMed  CAS  Google Scholar 

  • Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacol Berl 194:505–515

    Article  CAS  Google Scholar 

  • Janero DR, Vadivel SK, Makriyannis A (2009) Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. Int Rev Psychiatry 21:122–133

    Article  PubMed  Google Scholar 

  • Järbe TUC (1989) Discrimination learning with drug stimuli: methods and applications. In: Boulten AA, Baker GB, Greenshaw AJ (eds) Neuromethods, vol 13, Psychopharmacology. Humana Press, Clifton, pp 513–563

    Google Scholar 

  • Järbe TUC (2011) Perceptual drug discriminative aspects of the endocannabinoid signaling system in animals and man. In: Glennon RA, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley Publ. Co., Hoboken

    Google Scholar 

  • Järbe TUC, Lamb RJ (1995) Discriminated conditioned taste aversion for studying multi-element stimulus control. Behav Pharmacol 6:149–155

    PubMed  Google Scholar 

  • Järbe TUC, Lamb RJ (1999) Effects of lithium dose (UCS) on the acquisition and extinction of a discriminated morphine aversion: tests with morphine and delta-9-THC. Behav Pharmacol 10:349–358

    Article  PubMed  Google Scholar 

  • Järbe TUC, Sheppard R, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A (1998) Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. Behav Pharmacol 9:169–174

    PubMed  Google Scholar 

  • Järbe TUC, Lamb RJ, Lin S, Makriyannis A (2001) (R)-methanandamide and Δ9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacol Berl 156:369–380

    Article  Google Scholar 

  • Järbe TUC, Andrzejewski ME, DiPatrizio NV (2002) Interactions between the CB1 receptor agonist delta-9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73:911–919

    Article  PubMed  Google Scholar 

  • Järbe TUC, DiPatrizio NV, Li C, Makriyannis A (2003) The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav 75:809–821

    Article  PubMed  Google Scholar 

  • Järbe TUC, Harris MY, Li C, Liu Q, Makriyannis A (2004) Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacol Berl 177:35–45

    Article  Google Scholar 

  • Järbe TUC, Lamb RJ, Liu Q, Makriyannis A (2006a) Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog, in rats trained with ∆9-THC or (R)-methanandamide (AM-356). Psychopharmacol Berl 188:315–323

    Article  Google Scholar 

  • Järbe TUC, Liu Q, Makriyannis A (2006b) Antagonism of discriminative stimulus effects of delta-9-THC and (R)-methanandamide in rats. Psychopharmacol Berl 184:36–45

    Article  Google Scholar 

  • Järbe TUC, DiPatrizio NV, Li C, Makriyannis A (2007) Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats. Behav Pharmacol 18:673–680

    Article  PubMed  Google Scholar 

  • Järbe TUC, LeMay BJ, Olszewska T, Vemuri VK, Wood JT, Makriyannis A (2008a) Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav 91:84–90

    Article  PubMed  Google Scholar 

  • Järbe TUC, Li C, Vadivel SK, Makriyannis A (2008b) Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacol Berl 198:467–478

    Article  Google Scholar 

  • Järbe TUC, Li C, Liu Q, Makriyannis A (2009) Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog. Psychopharmacol Berl 203:229–239

    Article  Google Scholar 

  • Järbe TUC, Gifford RS, Makriyannis A (2010) Antagonism of THC-induced behavioral effects by rimonabant: time course studies in rats. Eur J Pharmacol 648:133–138

    Article  PubMed  Google Scholar 

  • Kirk RE (1968) Experimental design: procedures for the behavioral sciences, 2nd edn. Brooks/Cole, Belmont, CA

    Google Scholar 

  • Le Foll B, Goldberg SR (2004) Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. NeuroReport 15:2139–2143

    Article  PubMed  Google Scholar 

  • Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, Parker LA (2010) Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol 161:336–349

    Article  PubMed  CAS  Google Scholar 

  • Mansbach RS, Rovetti CC, Winston EN, Lowe JA 3rd (1996) Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacol Berl 124:315–322

    Article  CAS  Google Scholar 

  • McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, Betz AJ, Ishiwari K, Makriyannis A, Salamone JD (2003) The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14:583–588

    Article  PubMed  CAS  Google Scholar 

  • McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD (2005) The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacol Berl 180:286–293

    Article  CAS  Google Scholar 

  • McMahon LR (2006) Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Δ9-tetrahydrocannabinol. Psychopharmacol Berl 188:306–314

    Article  CAS  Google Scholar 

  • McMahon LR, Ginsburg BC, Lamb RJ (2008) Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Δ9-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacol Berl 198:487–495

    Article  CAS  Google Scholar 

  • Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, Piomelli D (2009) The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav 97:121–124

    Article  PubMed  CAS  Google Scholar 

  • Pério A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrié P (1996) Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 7:65–71

    Article  PubMed  Google Scholar 

  • Pertwee RG (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17:1360–1381

    Article  PubMed  CAS  Google Scholar 

  • Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, Peng Y, Olszewska T, Thakur GA, Makriyannis A, Parker LA, Salamone JD (2008) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946–955

    Article  PubMed  CAS  Google Scholar 

  • Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD (2009a) Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20:112–122

    Article  PubMed  Google Scholar 

  • Sink KS, Vemuri VK, Wood J, Makriyannis A, Salamone JD (2009b) Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 91:303–306

    Article  PubMed  CAS  Google Scholar 

  • Sink KS, Segovia KN, Collins LE, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD (2010) The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav 95:479–484

    Article  PubMed  CAS  Google Scholar 

  • Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306:93–102

    Article  PubMed  CAS  Google Scholar 

  • Solinas M, Goldberg SR, Piomelli D (2008) The endocannabinoid system in brain reward processes. Br J Pharmacol 154:369–383

    Article  PubMed  CAS  Google Scholar 

  • Tai S, Järbe TUC, Li C, Vadivel SK, Makriyannis A (2009) Discriminative stimulus functions of methanandamide and ∆9-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. International Cannabinoid Research Society

  • Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, Makriyannis A, Kunos G (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953–2966

    Article  PubMed  CAS  Google Scholar 

  • Thakur GA, Nikas SP, Li C, Makriyannis A (2005) Structural requirements for cannabinoid receptor probes. Hand Exp Pharm 168:209–246

    Article  CAS  Google Scholar 

  • Vemuri VK, Janero DR, Makriyannis A (2008) Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 93:671–686

    Article  PubMed  CAS  Google Scholar 

  • Welzl H, D'Adamo P, Lipp HP (2001) Conditioned taste aversion as a learning and memory paradigm. Behav Brain Res 125:205–213

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank the National Institute on Drug Abuse (NIDA), Bethesda, MD, USA for supplies of Δ9-THC and rimonabant, and also thanking Roger S. Gifford as well as three anonymous reviewers for their comments on earlier drafts of this manuscript. The studies were supported by NIDA Grants DA 09064, 03801, 9158, 7215, and 00493.

Disclosure Statement

All authors declare that there is no actual or potential conflict of interest related to this manuscript. 'Role of the funding source': Authors declare that the study sponsor did not have any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Author information

Authors and Affiliations

  1. Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, 116 Mugar Hall, 360 Huntington Ave., Boston, MA, 02115, USA

    Torbjörn U. C. Järbe, Brian J. LeMay, V. Kiran Vemuri, Subramanian K. Vadivel, Alexander Zvonok & Alexandros Makriyannis

Authors
  1. Torbjörn U. C. Järbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian J. LeMay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Kiran Vemuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Subramanian K. Vadivel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexander Zvonok
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexandros Makriyannis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Torbjörn U. C. Järbe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Järbe, T.U.C., LeMay, B.J., Vemuri, V.K. et al. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology 216, 355–365 (2011). https://doi.org/10.1007/s00213-011-2226-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-011-2226-3

Keywords

Search

Navigation